Please use this identifier to cite or link to this item:
|Title:||Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio a Syndrome: A Phase 3b Study||Authors:||Owens, Penny ;Bhattacharya, K.;Balasubramaniam, S.;Murray, K.;Peters, H.;Ketteridge, D.;Inwood, A.;Lee, J.;Ellaway, C.;Wong, M.||Affliation:||Central Coast Local Health District||Issue Date:||2020||Source:||8:e20200001||Journal title:||Journal of Inborn Errors of Metabolism and Screening||Department:||Paediatrics||Abstract:||Abstract The safety and efficacy of elosulfase alfa were evaluated in a multicenter, open-label, phase 3b study in Australian Morquio A patients, consisting of a 49-week initial phase and an extension phase until elosulfase alfa was government funded. Thirteen patients (1-27 years) were enrolled. No new safety concerns were identified over 138 weeks. Most drug-related adverse events were mild or moderate in severity; none led to study discontinuation. After 49 weeks of treatment, median improvements from baseline were seen in the 6-minute walk test (+41.0 m), 3-minute stair climb test (+14.0 stairs/min), forced vital capacity (+16.4%), forced expiratory volume in 1 second (+14.1%), urine keratan sulfate (-7.1 µg/mg creatinine), and pain intensity. Growth, cardiac function, sleep, and quality of life results were mixed or stable. These results provide further evidence of the acceptable safety/tolerability profile of elosulfase alfa. The improvements in endurance, pulmonary function, and pain support findings from previous studies.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1979||DOI:||10.1590/2326-4594-JIEMS-2020-0001||ISSN:||2326-4594||Publicaton type:||Journal Article||Study or Trial:||Multicentre Studies|
|Appears in Collections:||Health Service Research|
Show full item record
checked on Feb 2, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.